...
首页> 外文期刊>JACC. Cardiovascular imaging. >T2-weighted imaging to assess post-infarct myocardium at risk.
【24h】

T2-weighted imaging to assess post-infarct myocardium at risk.

机译:T2加权成像可评估梗塞后心肌的风险。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

To understand the amount of salvaged myocardium after reperfusion of acute myocardial infarction (Ml), it is essential to know the area of myocardium at risk (AAR) before reperfusion to assess salvaged myocardium as AAR minus final infarct size. Measuring myocardial salvage offers tremendous potential for development of novel pharmacologic agents that can reduce reperfusion injury and thereby increase myocardial salvage in reperfused Ml. In animal studies, dyes such as phthalocyanine blue injected directly into the coronary circulation have been used to assess AAR. In humans, contrast echocardiography has been used in the catheterization lab before reperfusion to make this measurement (1). Although accurate and useful, this technology is available in very few laboratories around the world on a moment's notice when a patient presents with an Ml. A technique to measure AAR in Ml that could be applied after reperfusion would be ideal. T2-weighted (T2-W) imaging by cardiac magnetic resonance (CMR) seems to be just such a technique, as demonstrated in the studies presented here in the iForum piece by Matthias Friedrich, MD. T2-weighted imaging is sensitive to myocardial edema, and it is thought that the area of edema can mark the original AAR. T2-weighted imaging was first applied in the mid-1990s, but it is only in the last few years that it has begun to hit its clinical stride.
机译:为了了解急性心肌梗塞(M1)再灌注后可挽救的心肌量,在再灌注前了解处于危险状态的心肌面积(AAR)至关重要,以将挽救后的心肌评估为AAR减去最终梗死面积。测量心肌抢救为开发新型药理剂提供了巨大的潜力,这些药物可以减少再灌注损伤,从而增加再灌注M1的心肌抢救率。在动物研究中,直接注入冠状动脉循环的染料如酞菁蓝已用于评估AAR。在人类中,在再灌注前已在导管实验室中使用对比超声心动图进行测量(1)。尽管准确且有用,但当患者出现M1时,该技术可在全世界极少的实验室中立即使用。可以在再灌注后应用在M1中测量AAR的技术是理想的。心脏磁共振(CMR)进行的T2加权(T2-W)成像似乎就是这样一种技术,正如医学博士Matthias Friedrich在iForum上发表的研究中所证明的那样。 T2加权成像对心肌水肿敏感,并且认为水肿区域可以标记原始AAR。 T2加权成像最初是在1990年代中期应用的,但是直到最近几年,它才开始取得临床进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号